NCT00945269 2022-11-15
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
Clinical Trials
5 trialsNCT01127451 2022-04-13
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Eisai Inc.
Phase 2 Completed
NCT00515528 2021-01-26
Vaccination Plus Ontak in Patients With Metastatic Melanoma
University of Chicago
Phase 2 Terminated
NCT00299689 2014-09-05
Phase II Trial of Ontak With Metastatic Melanoma
James Graham Brown Cancer Center
Phase 2 Completed
NCT00082914 2013-06-20
Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed